Led by Dr. Roger G. Owen, St. James’ University Hospital, Leeds, UK, and colleagues recently concluded that for those patients with treatment-naïve or relapsed/refractory Waldrenstrom Macroglobulinemia (WM), a type of non-Hodgkin lymphoma, single-agent acalabrutinib...